DSM-Firmenich completes buyback as DSM-Firmenich stock sits 0.75 percent below its high

Published on 10/07/2026 at 09:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The buyback totaled EUR 540.00 million on October 1, 2026. DSM-Firmenich stock costs EUR 99.75 on October 7, 2026 after EUR 99.32, plus 0.43 percent.

Bauhaus-Poster mit geometrischen Formen, Molekül und Schriftzug SCIENCE — dsm-firmenich AG (ISIN CH1216478797) erscheint als geometrisches Bauhaus-Poster mit Molekülformen und dem Wort SCIENCE, Illustration mit AI erstellt.

DSM-Firmenich stock stood at EUR 99.75 at Lang & Schwarz on October 7, 2026 at 9:20 a.m. CEST, 0.75 percent below its EUR 100.50 52-week high. The company completed its EUR 540.00 million share repurchase program on October 1, 2026, according to FinanzNachrichten.

Buyback cuts the share count

The program repurchased 7,169,147 shares at an average price of EUR 75.32, including 6,488,446 shares earmarked for capital reduction. DSM-Firmenich plans to cancel those shares by the end of the first quarter of 2027, reducing issued shares from 253,626,947 to 247,138,501, a planned 2.56 percent decline, the same FinanzNachrichten report states.

That arithmetic gives the transaction a direct per-share angle: the completed purchases averaged EUR 24.43 below the current Lang & Schwarz price. The planned cancellation could support earnings per share mechanically, but it does not by itself resolve the company's operating priorities.

Cash conversion tests the growth case

DSM-Firmenich reported EUR 4.66 billion of revenue from continuing operations in the first half of 2026, with adjusted EBITDA of EUR 900.00 million and a 19.30 percent margin, according to De Belegger. Comparable revenue growth reached 5.00 percent in the first half and 6.00 percent in the second quarter, while core adjusted earnings per share rose 14.00 percent to EUR 1.84.

The counterweight is cash conversion. Adjusted gross cash flow reached 7.00 percent of revenue in the first half, below the company's 11.00 percent to 12.00 percent target for 2026, as De Belegger reported. For investors, that gap matters because a higher margin creates less value when working capital and debt absorb the cash.

Analyst targets remain divided

Analyst expectations also show a wide valuation spread. A Simply Wall St update dated October 6, 2026 put its fair value at EUR 73.31, down 26.49 percent from the Lang & Schwarz price, while citing a Citi target of EUR 111.00, a Bernstein target of EUR 103.00 and a JPMorgan target of EUR 68.00.

The same Simply Wall St update said Bernstein had an Outperform rating and JPMorgan retained an Underweight stance. The divergence makes cash delivery more important than the buyback alone: a smaller share count can improve per-share results, but only sustained revenue and cash growth can narrow the gap between bullish and cautious valuation cases.

Stock stays near yearly high

At EUR 99.75, DSM-Firmenich's market capitalization was EUR 24.6 billion on October 7, 2026, and its 52-week range was EUR 55.22 to EUR 100.50. The current price was EUR 0.43 above the Lang & Schwarz prior close of EUR 99.32 on October 6, 2026, equal to a plus 0.43 percent daily change.

DSM-Firmenich is listed on Euronext Amsterdam and SIX Swiss Exchange. Its next valuation test is whether the second half converts the first-half margin and revenue progress into cash, while the share cancellation provides a separate, measurable reduction in the issued share base.

The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.